Published: 2019 April 09

Dyslipidemia Market

SKU : PH71
180 pages
Report Summary
Table of Contents

Dyslipidemia Market is segmented By Drug Class (Statins, Cholesterol Absorption Inhibitors, Niacins, Fibric Acid, Omega-3 Fatty Acid Derivatives, Dyslipidemia Injectable), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2022-2029.

Dyslipidemia market is set to grow at a CAGR of 10% during the forecast period.

  • According to WHO, one-third of ischaemic heart disease is attributed to high cholesterol. 

  • Dyslipidemia is a condition characterized by abnormally elevated cholesterol or lipids (fats) in the blood. Dyslipidemias may be Primary that is genetic or Secondary, which is caused by lifestyle and other factors. Raised cholesterol increases the risks of heart disease and stroke.

Dyslipidemia Market



Market CAGR


Segments Covered

By Drug Type, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Dyslipidemia Market Growth

  •  The market is primarily driven by increase in prevalence of dyslipidemia worldwide, increasing awareness, and changing lifestyle. However, high drug prices acts as a major barrier to market growth with statins being the most expensive lipid-lowering medicines.

  • Several opportunities exist in the market for cost-effective therapies. The focus is on new drugs called PCSK9 inhibitors that reduce the amount of harmful LDL cholesterol circulating in the bloodstream.

Dyslipidemia Market Segmentation

  • The global Dyslipidemia market report segments the market by drug class, by distribution channel, and by region.

  • Dyslipidemia market based on drugs class is segmented into Statins, Cholesterol Absorption Inhibitors, Niacins, Fibric Acid, Omega-3 Fatty Acid Derivatives, and Dyslipidemia Injectable. During 2017, the statins segment dominated the market.

  • Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW. North America is the leading market for Dyslipidemia and driven by increasing patient pool and the change in the American Heart Association guidelines for the treatment of abnormal cholesterol levels.

  • The report also profiles the following companies in the Dyslipidemia market – AstraZeneca, Merck, Pfizer, Sanofi, Bayer, Abbott Laboratories, Mylan, Novartis, Amgen, Bristol-Myers Squibb Company, Shionogi, Takeda Pharmaceutical, Teva Pharmaceutical.


Frequently Asked Questions

What is the Projected CAGR value of the Dyslipidemia Market?

Dyslipidemia Market is expected to grow at a CAGR of 10% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Dyslipidemia Market during 2022-2029

Which is the fastest growing region in the Dyslipidemia Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Sickle Cell Treatment Market

Serum Separation Gel Market

Allogeneic Stem Cells Market

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy